Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
MapLight Therapeutics, Inc. (MPLT) is the subject of a Schedule 13G in which Nan Fung Group–affiliated reporting persons collectively report beneficial ownership, as reflected on Nan Fung Group Holdings Limited’s cover page, of 2,915,874 shares of common stock, representing 5.5% of the class.
The filing states that Pivotal bioVenture Partners Fund II, L.P. directly holds 611,446 shares, NFLS Beta Limited directly holds 671,606 shares, and Permwell Management Limited directly holds 1,628,722 shares of MapLight Therapeutics common stock. The ownership percentages are based on 52,848,208 voting common shares outstanding.
Key Figures
Beneficial ownership (NFGHL):2,915,874 shares of Common StockBeneficial ownership percentage (NFGHL):5.5%Pivotal bioVenture Partners Fund II, L.P. holdings:611,446 shares of Common Stock+5 more
8 metrics
Beneficial ownership (NFGHL)2,915,874 shares of Common StockShares beneficially owned as reported on Nan Fung Group Holdings Limited’s cover page
Beneficial ownership percentage (NFGHL)5.5%Percentage of MapLight Therapeutics voting Common Stock class
Pivotal bioVenture Partners Fund II, L.P. holdings611,446 shares of Common StockShares directly held by Pivotal bioVenture Partners Fund II, L.P. (1.2%)
NFLS Beta Limited holdings671,606 shares of Common StockShares directly held by NFLS Beta Limited (1.3%)
Permwell Management Limited holdings1,628,722 shares of Common StockShares directly held by Permwell Management Limited (3.1%)
Total voting Common Stock outstanding52,848,208 sharesOutstanding MapLight Therapeutics voting Common Stock used for percentage calculations
Existing outstanding shares before private placement43,650,321 sharesVoting Common Stock outstanding as of August 7, 2026
Shares issued in private placement9,197,887 sharesAdditional voting Common Stock issued in a private placement
"MapLight Therapeutics, Inc. is the subject of a Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficial ownershipfinancial
"The information required by this item with respect to each Reporting Person is set forth"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerfinancial
"6 | Shared Voting Power 2,915,874.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"8 | Shared Dispositive Power 2,915,874.00"
exempted limited partnershipfinancial
"Pivotal II is a Cayman Islands exempted limited partnership"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who are the main reporting persons in the MPLT Schedule 13G?
The Schedule 13G for MPLT is filed by Nan Fung Group Holdings Limited and related entities, including NF Investment Holdings Limited, Nan Fung Life Sciences Holdings Limited, NFLS Platform Holdings Limited, Pivotal Life Sciences Holdings Limited, Pivotal Partners Ltd, Pivotal bioVenture Partners Fund II, L.P., NFLS Beta Limited, and Permwell Management Limited.
How many MPLT shares do the Nan Fung reporting persons beneficially own?
The cover page for Nan Fung Group Holdings Limited reports beneficial ownership of 2,915,874 shares of MapLight Therapeutics common stock, representing 5.5% of the outstanding voting common stock, including shares held through several affiliated entities.
What percentage of MapLight Therapeutics (MPLT) does each key entity hold directly?
According to the filing, Pivotal bioVenture Partners Fund II, L.P. directly holds 611,446 shares (1.2%), NFLS Beta Limited directly holds 671,606 shares (1.3%), and Permwell Management Limited directly holds 1,628,722 shares (3.1%) of MPLT common stock.
What total share count is used to calculate ownership percentages for MPLT in this Schedule 13G?
Ownership percentages are based on 52,848,208 shares of voting common stock outstanding, comprised of 43,650,321 shares outstanding as of August 7, 2026 and 9,197,887 shares issued in a private placement reported on August 13, 2026.
Do the reporting persons have sole or shared voting power over MPLT shares?
For each reporting person, the cover pages state 0 shares of sole voting power and various amounts of shared voting power, such as 2,915,874 shares of shared voting power for Nan Fung Group Holdings Limited, indicating voting and dispositive power is held on a shared basis.
Which entities directly hold MPLT shares under the Nan Fung structure?
The filing states that Pivotal bioVenture Partners Fund II, L.P., NFLS Beta Limited, and Permwell Management Limited directly hold MPLT common stock, while upstream entities such as NFGHL, NFIHL, Nan Fung Life Sciences, NFLS Platform, and Pivotal Life Sciences hold indirect interests through ownership chains.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
MapLight Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
56565P103
(CUSIP Number)
08/13/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Nan Fung Group Holdings Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
VIRGIN ISLANDS, BRITISH
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,915,874.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,915,874.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,915,874.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
NF Investment Holdings Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
VIRGIN ISLANDS, BRITISH
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,911,774.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,911,774.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,911,774.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Nan Fung Life Sciences Holdings Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
VIRGIN ISLANDS, BRITISH
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,283,052.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,283,052.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,283,052.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
NFLS Platform Holdings Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
671,606.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
671,606.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
671,606.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Pivotal Life Sciences Holdings Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
611,446.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
611,446.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
611,446.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Pivotal Partners Ltd
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
611,446.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
611,446.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
611,446.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Pivotal bioVenture Partners Fund II G.P. Ltd
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
611,446.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
611,446.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
611,446.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Pivotal bioVenture Partners Fund II, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
611,446.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
611,446.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
611,446.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
NFLS Beta Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
VIRGIN ISLANDS, BRITISH
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
671,606.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
671,606.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
671,606.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
56565P103
1
Names of Reporting Persons
Permwell Management Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,628,722.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,628,722.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,628,722.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.1 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
MapLight Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
800 Chesapeake Drive, Redwood City, CA 94063
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of common stock, par value $0.0001 per share (the "Common Stock") of MapLight Therapeutics, Inc. (the "Issuer") are:
(i) Nan Fung Group Holdings Limited ("NFGHL")
(ii) NF Investment Holdings Limited ("NFIHL")
(iii) Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences")
(iv) NFLS Platform Holdings Limited ("NFLS Platform")
(v) Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences")
(vi) Pivotal Partners Ltd ("Pivotal Partners")
(vii) Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal II GP")
(viii) Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II," and together with Pivotal Life Sciences, Pivotal Partners, and Pivotal II GP, the "Pivotal Entities")
(ix) NFLS Beta Limited ("NFLS Beta")
(x) Permwell Management Limited ("Permwell")
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Pivotal Entities is 501 Second Street, Suite 200, San Francisco, CA 94107. The principal business address of each of NFGHL and Permwell is 17th Floor, AIRSIDE, 2 Concorde Road, Kai Tak, Hong Kong. The registered office address of each of NFIHL, Nan Fung Life Sciences and NFLS Beta is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. The registered office address of NFLS Platform is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands.
(c)
Citizenship:
Pivotal II is a Cayman Islands exempted limited partnership. Pivotal II GP is a Cayman Islands exempted company. Pivotal Partners is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Nan Fung Life Sciences, NFIHL, NFGHL, and NFLS Beta are incorporated in the British Virgin Islands. NFLS Platform and Permwell are incorporated in the Cayman Islands.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
56565P103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. Pivotal II directly holds 611,446 shares of Common Stock. NFLS Beta directly holds 671,606 shares of Common Stock. Permwell directly holds 1,628,722 shares of Common Stock.
Pivotal II GP is the general partner of Pivotal II, and is wholly owned by Pivotal Partners. Pivotal Partners is wholly owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly owned by NFIHL, which is wholly owned by NFGHL. NFLS Beta is wholly owned by NFLS Platform, which is wholly owned by Nan Fung Life Sciences. Permwell is wholly owned by NFIHL.
The members of the Executive Committee of NFGHL (the "Excomm") make investment decisions with respect to the securities of the Issuer held by NFLS Beta and Permwell. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Heqing Huang and Mr. Chun Wai Nelson Tang are the members of the Excomm. The members of the Excomm and the members of the Life Sciences Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal II. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Life Sciences Committee of NFGHL.
The amounts set forth in Rows 5 through 9 of the cover page of NFGHL also reflect 3,500 shares of Common Stock held by Mr. Bisgaard and 600 shares of Common Stock held by Mr. Hopfner. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock held by Messrs. Bisgaard and Hopfner.
(b)
Percent of class:
The information required by this item with respect to each Reporting Person is set forth in Row 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 52,848,208 shares of voting Common Stock outstanding, consisting of (i) 43,650,321 shares of voting Common Stock outstanding as of August 7, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2026 and (ii) 9,197,887 shares of voting Common Stock issued by the Issuer in a private placement, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on August 13, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by this item with respect to each Reporting Person is set forth in Row 5 of the cover pages to this Schedule 13G.
(ii) Shared power to vote or to direct the vote:
The information required by this item with respect to each Reporting Person is set forth in Row 6 of the cover pages to this Schedule 13G.
(iii) Sole power to dispose or to direct the disposition of:
The information required by this item with respect to each Reporting Person is set forth in Row 7 of the cover pages to this Schedule 13G.
(iv) Shared power to dispose or to direct the disposition of:
The information required by this item with respect to each Reporting Person is set forth in Row 8 of the cover pages to this Schedule 13G.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
